Using engineered bacteria to create vaccines for oral cancer treatment.
Engineered bacterial in situ vaccines against oral cancer.
This study is exploring a new way to help treat oral cancer by using specially designed bacteria to boost your immune system right where the tumor was removed, which could make the treatment more effective and safer for you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11035580 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating oral cancer by using engineered bacteria as in situ vaccines. The goal is to enhance the immune response at the site of tumor removal, thereby improving the effectiveness of immunotherapy while reducing the risk of systemic side effects. By localizing the treatment to the tumor-draining lymph nodes and the resection site, the study aims to reverse the immunosuppressive environment that often follows surgery. Patients may benefit from a more targeted and less toxic treatment option compared to traditional systemic therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients diagnosed with oral cancer who are undergoing surgical resection.
Not a fit: Patients with advanced metastatic oral cancer or those who are not surgical candidates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective immunotherapy option for patients with oral cancer.
How similar studies have performed: Other research has shown promise in using localized immunotherapy approaches, but this specific method using engineered bacteria is relatively novel.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Young, Simon — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Young, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.